Skip to main content
Caplight Logo









Cantex Pharmaceuticals

Cantex Pharmaceuticals

Private
Weston, FloridaHealthcare & Life Scienceshttps://cantex.com/

Last Round

Series D

Nov 12, 2014

Total Funding Raised

$30.92M

Company Overview

Cantex Pharmaceuticals is a biotechnology company that develops biopharmaceutical technologies designed to improve the treatment of cancers and other life-threatening disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B2C

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

RAGE inhibitorazeliragonclinical-stage pharmadrug developmentcancer therapyinflammatory lung diseasesmall molecule drugbiotech companydrug repurposingoral drugorphan drug designationpancreatic cancerglioblastomaReceptor for Advanced Glycation End-products

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cantex Pharmaceuticals Comparables

Compare Cantex Pharmaceuticals with similar companies based on industry and business-model similarity.

Cantex Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RAGE Biotech
77%
Arrowhead Pharmaceuticals
69%
RAPT Therapeutics
66%

Cantex Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DNov 12, 2014
Series CApr 11, 2014
GrantNov 3, 2010
Series BAug 25, 2006
Series AAug 12, 2002

Key People

Founding team and executive leadership

Stephen Marcus

Chief Executive Officer

Executive Team

Steve M

Chief Executive Officer

Executive Team

Cantex Pharmaceuticals Investors

Notable investors and investment history

Cantex Pharmaceuticals investors
InvestorRounds
Research Corporation TechnologiesSeries B, Series C, Series A
Domain AssociatesSeries B, Series C, Series D
CHL Medical PartnersSeries B, Series C
The Aurora FundsSeries B, Series C, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors grew 31% MoM, reaching 1.9K.

  • Apr 24, 2026

    Monthly visitors increased 670% MoM.

Cantex Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cantex Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cantex Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersWeston, Florida
Employee Range4
Year Founded2002
Last FundingNov 12, 2014

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?